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A variety of stimuli including chemicals,
extremes in osmolarity, elevated H+ ion con-
centrations as well as mechanical stimuli are
sensed by afferent neurons that innervate the
airways. These stimuli evoke action potentials
at the peripheral terminals of afferent neurons
that are conducted to the central nervous sys-
tem, therein causing release of neurotransmit-
ters that excite secondary neurons in the brain
stem or spinal cord, leading to homeostatic
and defensive reflexes. Reflexes initiated in
the airways include sneezing, coughing,
changes in autonomic drive, and alterations
in the depth and pattern of breathing.
In a number of tissues and organs, the var-
ious anatomic and physiologic characteristics
of afferent fibers do not appear to be static
properties, but rather appear to change rapidly
in response to inflammation (1–5). In this
overview, literature relevant to inﬂammation-
induced anatomic and physiologic plasticity of
airway primary afferent neurons is discussed.
Anatomy and Physiology 
of Airway Afferent Nerves
There are several subtypes of afferent ﬁbers in
the airways (6–8), and it is difﬁcult to devise
an unambiguous classification scheme that
takes all features of these ﬁbers into account
(9). One scheme classifies afferent fibers
according to the location of their cell bodies.
For example, the nasal mucosa is innervated
by sensory neurons whose cell bodies reside in
the trigeminal ganglion (10,11), whereas those
that innervate the trachea and bronchus have
cell bodies residing in inferior (nodose) or
superior (jugular) vagal ganglia (12). Although
some afferent neurons that innervate the lung
have cell bodies that reside in dorsal root gan-
glia (12,13) few studies have concentrated on
the spinal innervation of the airways.
Afferent fibers innervating the airways
may also be broadly classiﬁed into two physi-
ologic types: those that monitor normal
physiologic activity and those activated by
potentially damaging noxious stimuli.
Afferent fibers that can be activated by
mechanical forces occurring during normal
respiration include slowly adapting stretch
receptors (SARs) and rapidly adapting recep-
tors (RARs). Activation of SARs leads to inhi-
bition of inspiration, relaxation of airway
smooth muscle, peripheral vasodilation, and
tachycardia (7,8). Activation of RARs leads to
increased inspiratory effort, contraction of
airway smooth muscle, and secretion by air-
way submucosal glands (7,8). Afferent ﬁbers
activated by noxious stimuli and by mediators
associated with tissue damage and inﬂamma-
tion include some thinly myelinated Aδ -ﬁbers
and unmyelinated C ﬁbers. Reﬂexes resulting
from activation of these ﬁbers include inhibi-
tion of inspiration and expiration (causing an
initial apnea followed by rapid shallow
breathing), bronchoconstriction, an increase
in bronchial blood ﬂow, and bradycardia (8). 
In the guinea pig, airway afferent fibers
whose cell bodies reside in the nodose ganglia
appear to correspond to myelinated fibers
that monitor normal physiologic activity.
They are exquisitely sensitive to mechanical
stimuli but do not respond to a variety of
chemical stimuli, including capsaicin and
bradykinin (Figure 1) (14). By contrast, the
jugular ganglia contain the cell bodies of
myelinated Aδ fibers and unmyelinated C
fibers. Jugular afferent fibers innervating
guinea pig airways resemble the nociceptive
fibers of the somatosensory system in that
they have relatively high thresholds to
mechanical stimuli, but respond vigorously to
classic nociceptive ﬁber-selective stimuli such
as capsaicin and bradykinin (Figure 1) (14). 
A subset of airway afferent neurons not
only participate in centrally mediated reﬂexes,
but are also thought to release neuropeptides
at their peripheral terminals. The locally
released peptides can activate neurokinin
(NK) receptors in a variety of airway tissue
and cell types, leading to alterations in bron-
chomotor tone, mucus secretion, and neuro-
genic inflammation. The predominant
neuropeptides found in this subset of airway
afferent ﬁbers are calcitonin gene-related pep-
tide (CGRP) and the tachykinins substance P
and NK-A (15). Under normal conditions
the tachykinergic innervation to the airways is
thought to be derived exclusively from neu-
rons that project nociceptive-like C ﬁbers. In
the guinea pig and rat airways, the cell bodies
of the vagal afferent fibers that contain
tachykinins are C fibers whose cell bodies
reside in the jugular ganglia (12,14,16,17).
Inﬂammation and the
Excitability of Afferent Neurons
The threshold of primary afferent neurons to
various stimuli is not ﬁxed, but rather can be
become sensitized during inflammation (4).
Perhaps the most dramatic examples of this
sensitization occur when an inflammatory
mediator fails to overtly stimulate action
potentials, but inﬂuences the nerve ending in
such a way that the nerve responds to stimuli
that were previously subthreshold. This is
known to occur following experimental
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arthritis in rats, where afferent neurons that
normally fail to respond even to noxious rota-
tion of a rat joint respond to simple flexion
following arthritis (18,19). Likewise, afferent
ﬁbers insensitive to mechanical distension of
the bladder respond to modest distension fol-
lowing inﬂammation (20). Allergic rhinitis is
associated with increased nasal neural respon-
siveness to stimuli that evoke sneezing, the
nasonasal secretory reflex, and axon
reﬂex–mediated plasma extravasation (Figure
2) (21). In the human upper airway sub-
threshold concentrations of a sensory nerve
irritant reach threshold and evoke autonomic
and sneezing reﬂexes when applied during the
time of allergic inﬂammation (22).
Increases in afferent nerve excitability may
contribute to the responsiveness of the airway
to various bronchoconstrictor stimuli. Airway
hyperresponsiveness is a key feature of asthma
and is deﬁned as that phenomenon reﬂected in
a substantial increase in the resistance to air-
ﬂow in response to a bronchoconstrictive stim-
ulant at doses that have little or no effect in the
nonasthmatic population. Many mediators
found in the inflamed airways of asthmatics
may modulate the sensitivity of afferent neu-
rons. This has led to speculation that analogies
may be drawn between asthma-associated air-
way hyperresponsiveness and hyperalgesia
(heightened sensitivity to painful stimuli) that
often accompanies inflammation in the
somatosensory system (23). Most stimuli
administered to assess airway hyperresponsive-
ness, including histamine (24,25), capsaicin
(26), bradykinin (27), distilled water (28), and
sulfur dioxide (29), cause bronchoconstriction
by stimulating primary afferent nerve fibers
and initiating central parasympathetic cholin-
ergic reﬂexes. Experiments in animal models
suggest that even the response to a so-called
direct smooth muscle spasmogen like metha-
choline is likely to be mediated in part by a
centrally mediated cholinergic reflex (30). It
follows, therefore, that an increase in the
excitability of the afferent endings associated
with inﬂammation in the airway wall will lead
to a heightened reﬂex bronchoconstriction at a
given dose of stimulant and thereby contribute
to airway hyperreactivity.
Studies of respiratory viral infections
support the hypothesis that the afferent inner-
vation of the lung contributes to certain types
of hyperresponsiveness. Respiratory tract viral
infections are often associated with exacerba-
tions of asthma and the induction of
bronchial hyperresponsiveness in otherwise
healthy subjects (31–35). The reasons for this
association are yet to be resolved and appear
to involve multiple mechanisms (36) includ-
ing increases in the excitability of airway affer-
ent neurons. Empey and co-workers (35)
reported that respiratory viral infections cause
subjects to develop airway hyperresponsive-
ness to inhaled histamine. The observation
that muscarinic cholinoceptor antagonist
atropine prevented this response suggests the
exaggerated bronchoconstriction was due to
an increase in the excitability of afferent neu-
rons that innervate the airways, leading to
enhanced parasympathetic, cholinergic
reﬂex–mediated bronchoconstriction. This is
supported by their observation that the
threshold concentration of citric acid that pro-
duced cough in subjects with viral infections
was signiﬁcantly lower than in control subjects
or in subjects after recovery from infection.
These observations suggest that respiratory
tract viral infections can sensitize the airway
afferent fibers that initiate reflex broncho-
constriction and cough.
The mechanisms underlying increases in
excitability of nerve endings at the sites of
airway inflammation are not known. In an
in vitro study on airway nerve endings, the
mechanical sensitivity of Aδ -fibers innervat-
ing guinea pig isolated trachea from
immunologically sensitized animals
increased following exposure to the relevant
antigen (37). In this model, exposure of the
trachea/bronchus to the relevant antigen
results in inflammatory mediator release,
but does not overtly activate the afferent
nerve endings. Rather, antigen challenge
increases the excitability of the nerve end-
ings, resulting in a 4-fold decrease in the
amount of mechanical force required to
activate the nerve fibers (37). In general
terms the data available on this subject are
compatible with the hypothesis that various
Figure 1. In the guinea pig, airways afferent ﬁbers whose cell bodies reside in the nodose ganglia have large cell
bodies, are myelinated, conduct actions potentials in the Aδ range and are exquisitely sensitive to mechanical stimuli
but do not respond to a variety of chemical stimuli including capsaicin and bradykinin. These ﬁbers appear to corre-
spond to those ﬁbers that monitor normal activity during breathing. In contrast, the jugular ganglia contain cell bodies
of myelinated Aδ and unmyelinated C ﬁbers. These jugular ﬁbers resemble the nociceptive ﬁbers of the somatosen-
sory system in that they have relatively high thresholds to mechanical stimuli and respond to classic nociceptive
ﬁber-selective stimuli such as capsaicin and bradykinin. *Under normal conditions the tachykinergic innervation to
the guinea pig bronchus is derived almost exclusively from C ﬁbers whose cell bodies reside in the jugular ganglia.
However, following allergen-induced airway inflammation or intratracheal instillation of NGF, the cell bodies of
myelinated A-ﬁbers were also found to contain immunoreactive substance P. Thus it appears that after inﬂammation,
non-nociceptive (nodose ﬁbers) as well as nociceptive-like (jugular ﬁbers) airway afferent ﬁbers contain tachykinins.
Based on data from Riccio et al. (14), Hunter et al. (16), and Fischer et al. (17).
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Figure 2. Central reﬂex induced by increasing doses of capsaicin applied, using ﬁlter paper discs, onto the right nasal
septum. The changes between diluent- and capsaicin-induced secretions collected at the right (ipsilateral) and left
(contralateral) septal mucosae are shown, depicting a 2-log greater responsiveness in the rhinitis group. The dose of
capsaicin that induced at least 50% of the maximum response (ED50) was signiﬁcantly lower in subjects with allergic
rhinitis compared with the healthy volunteers. Figure reprinted from Sanico et al. (21) with permission of S. Karger AG.
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inflammatory mediators bind to receptors
on the nerve endings and modulate current
flow through various types of ion channels
(38). Inflammation-induced changes in the
viscoelastic properties of the airway wall
may also contribute to increased excitability
of afferent nerves (39).
Inﬂammation, Tachykinin
Levels, and the Density 
of Afferent Innervation
An increase in the content of tachykinins is
commonly seen in inﬂamed tissues (1,40–43).
With respect to airways the baseline amount of
substance P in human nasal lavage was greater
in atopic subjects with grass pollen allergy than
in healthy nonallergic subjects, and allergen
challenge elevated these levels further (44).
The concentration of substance P in the spu-
tum of patients with chronic obstructive pul-
monary disease or asthma was also greater that
than found in the sputum of healthy volun-
teers (45). Heaney and co-workers, however,
found no immunoreactive substance P or
CGRP in bronchoalveolar lavage ﬂuid (BALF)
of asthmatics or control subjects. However,
they did find NK-A, and the levels of this
tachykinin were similar in BALF from asth-
matics and healthy subjects (46). Lilly and co-
workers found signiﬁcantly less substance P in
lung tissue from asthmatics compared with
nonasthmatics (47). One possible explanation
for these conﬂicting data may be variable pro-
teolytic breakdown of tachykinins within the
airways. An alternative method of assessing
the expression of tachykinins may be to quan-
titate the levels of tachykinin immuno-
reactivity or mRNAs encoding tachykinin
precursor peptides in the cell bodies of affer-
ent neurons. This approach has been useful in
studies of rodents (see below). 
The influence of inflammation on the
density of the neuropeptide-containing inner-
vation to the human airways is controversial.
Nasal turbinate blood vessels from rhinitic
children were more richly innervated with
CGRP immunoreactive fibers than those
from nonrhinitic children (48). The density
of substance P immunoreactive nerves in the
airway mucosa of asthmatics has also been
reported to be increased (49), although this is
not consistently observed (50,51). More
recently, Chu and co-workers (52) also found
that substance P was present in greater levels
in the subepithelial airway mucosa of asth-
matics compared with healthy control sub-
jects; however, they did find a significantly
greater level of immunoreactive substance P
in the airway epithelium of asthmatics. 
Induction of Tachykinin
Synthesis in Afferent Neurons 
Although nonneuronal sources of tachy-
kinins may contribute to elevated levels of
NKs in inflamed airways [for example some
inﬂammatory cells can synthesize tachykinins
(53)], there is accumulating evidence that
irritation and inflammation of the airways
can induce the synthesis of tachykinins in
afferent neurons. 
An example of this induction was demon-
strated following exposure of the rat nasal
mucosa to toluene diisocyanate (TDI) (54), a
chemical used in the production of
polyurethane polymers, plastics, foams, and
adhesives. Exposure to TDI is associated with
nasal irritation, rhinitis, and occupational
asthma, and there is some evidence from ani-
mal models that activation of afferent C ﬁbers
plays a role in these responses (55). Acute
exposure to inhaled TDI is associated with
increased levels of mRNA encoding
tachykinin precursor peptides in cell bodies of
afferent ﬁbers that innervate nasal mucosa as
well as an increased density of substance P
immunoreactive nerve fibers in rat nasal
epithelium (54). These data suggest that expo-
sure of airway epithelium to inhaled irritants
can lead to increases in neuropeptide gene
transcription and translation within the neu-
ronal cell bodies located in sensory ganglia.
Allergen-induced inflammation of the
airways may also stimulate the neuronal syn-
thesis of tachykinins in sensory ganglia. In
sensitized guinea pigs, challenge of the nasal
mucosa with the sensitizing allergen enhanced
the synthesis of substance P and CGRP in the
cell bodies of trigeminal ganglion neurons and
the axonal transportation of these peptides to
their terminals in the nasal mucosa (56).
Similarly, within 24 hr of allergen inhalation,
there is a 3- to 5-fold elevation in the amount
of substance P, NK-A and CGRP immunore-
activity in the lungs of guinea pigs (17).
Although decreased enzymatic breakdown of
tachykinins within the airways may contribute
to this elevation (57), at least a component of
the increased content of tachykinins stems
from an increase in tachykinin synthesis (17).
A somewhat surprising observation was that,
following allergen challenge, nodose neurons
whose axons projected to the airways were
shown to express tachykinins. This was sur-
prising, as nodose ﬁbers that innervate guinea
pig airways do not normally contain
immunoreactive tachykinins. In sensitized
guinea pigs not challenged with antigen, only
1% of cell bodies of airways innervating
nodose fibers were immunoreactive for sub-
stance P. In challenged guinea pigs, approxi-
mately 10% of cell bodies of nodose neurons
retrogradely labeled from the airways were
immunoreactive for substance P (17).
Physiologic studies support the hypothesis
that allergic inﬂammation causes a substantive
qualitative change in the type of airway affer-
ent fibers that contained tachykinins, such
that non-nociceptive (capsaicin-insensitive,
low-threshold mechanosensors) as well as
nociceptive airway afferent ﬁbers contribute to
the neuropeptide innervation (Figure 1) (58).
The implications of this qualitative difference
are discussed below in the section on
enhanced release of tachykinins.
The mechanism by which airway exposure
to allergens or inhaled irritants leads to
increases in neuropeptide synthesis within cell
bodies of remotely located ganglia is
unknown. A family of molecules known to act
on nerve endings to send growth signals to
their cell bodies is the neurotrophins.
Neurotrophins [e.g., nerve growth factor
(NGF), brain derived neurotrophic factor,
neurotrophin 3 and 4] support the survival,
differentiation, and function of neurons of the
central and peripheral nervous system (59).
Inﬂammation of the airways is associated with
increased levels of neurotrophic factors that
may stimulate plasticity in afferent innerva-
tion. Potential cellular sources for this increase
in airway neurotrophins include the respira-
tory epithelium, T lymphocytes, alveolar
macrophages, and mast cells (60–62).
Neurotrophins initiate their effects in vagal
afferent neurons, in part, by binding to high-
afﬁnity receptors of the tyrosine kinase family,
followed by uptake and retrograde transport
to the cell body in the vagal ganglia (63).
Among the family of neurotrophins most
attention has been given to NGF as a poten-
tial mediator in afferent plasticity in inﬂamed
airways. NGF is found in human airways, and
the NGF content of airway lavage fluid is
increased following allergen challenge
(61,64–66). NGF is capable of regulating the
expression of mRNAs encoding the precursors
of substance P and CGRP in mature afferent
neurons (67). Moreover, instillation of NGF
into the trachea of guinea pigs was associated
with a greater percentage of airway-specific
afferent neurons that express immunoreactive
substance P and also lead to a qualitative
switch in the nature of the nodose afferent
neurons (16), results similar to those following
allergen challenge. That is, after NGF expo-
sure, non-nociceptive–like (nodose ﬁbers) as
well as nociceptive-like (jugular ﬁbers) airway
afferent ﬁbers contained tachykinins.
Enhanced Release 
of Tachykinins
The release of tachykinins from the peripheral
terminals of C ﬁbers in the airways is thought
to occur via an axon reflex. An axon reflex
occurs when stimulation of a C ﬁber ending
results in action potentials which, in addition
to traveling orthodromically toward the cen-
tral nervous system, also travel antidromically
via collateral branches to effect the release of
tachykinins. The release of tachykinins from
the peripheral terminals of afferent nerves can
be induced by a variety of stimuli including
Environmental Health Perspectives • VOLUME 109 | SUPPLEMENT 4 | August 2001 569Carr and Undem
570 VOLUME 109 | SUPPLEMENT 4 | August 2001 • Environmental Health Perspectives
capsaicin (68), bradykinin (69), electrical
nerve stimulation (70), cigarette smoke (71),
low pH (72), and hypertonic saline (73). The
release of tachykinins from the peripheral ter-
minals of C ﬁbers in the airways may result in
increased blood ﬂow through the microvascu-
lar bed of the airways, increased microvascular
permeability, inﬂammatory cell recruitment,
stimulation of airways secretions, and airway
smooth muscle contraction (74).
There is some evidence to suggest inﬂam-
mation of the airways can enhance the release
of tachykinins from the peripheral terminals of
vagal afferent neurons. In guinea pig isolated
airway preparations, speciﬁc allergen, at a con-
centration that caused only a threshold level of
mediator release, profoundly elevated
tachykinergic nerve-mediated contraction of
airways smooth muscle (70). This was inde-
pendent of tachykinin synthesis (the cell bod-
ies were removed); however, it was mimicked
by histamine. Moreover, the histamine H1
receptor-selective antagonist pyrilamine could
prevent and reverse the antigen-induced
potentiation. Other mast cell mediators such
as the cysteinyl leukotrienes (Cys-LTs) may
also contribute to allergen-induced potentia-
tion of tachykinergic nerve-mediated responses
in the airways via the activation of Cys-LT1
receptors on afferent nerve endings (70,75,76).
Respiratory tract infections may also
intensify the tachykinergic nerve-mediated
responses in the airways. Infections with
Mycoplasma pulmonis can produce a 30-fold
increase in the magnitude of neurogenic
plasma extravasion in rat airways (Figure 3)
(77). Similarly, respiratory infections of
rodents with Sendai virus (parainfluenza
type 1) can potentiate substance P–induced
increases in airways blood flow (78) and
enhance tachykinergic nerve-mediated con-
traction of airway smooth muscle (79). These
effects appear to be at least partially due to
decreased activity of neutral endopeptidase, a
protease normally present in the airways,
which degrades tachykinins (80–82). 
Although much less studied, neuropep-
tide release from the central terminals of
afferent fibers in the brain stem may have
more influence on airway physiology than
neuropeptide release from their peripheral
terminals in the airway wall. The primary
neurotransmitter released from the central
terminals of vagal airway afferent neurons
appears to be glutamate (83). In the
somatosensory system, tachykinins act as neu-
romodulators that enhance the excitability of
secondary neurons to primary neurotransmit-
ters, thereby enhancing the perception of
pain and/or reﬂex responses to noxious stim-
uli (84). Relatively little work has been pub-
lished on the mechanisms by which NKs
modulate synaptic neurotransmission in the
brain stem. Nevertheless, pharmacologic
studies have demonstrated that the NK recep-
tors NK1, NK2, and NK3 are present in sec-
ondary neurons within the nucleus of the
solitary tract, and stimulation of these recep-
tors can profoundly affect vagal reﬂex physi-
ology (85). Also consistent with a role for
tachykinins in modulating airway reﬂexes, the
NK1 receptor–selective antagonist CP-99,994
and SR-48968, an NK2 receptor–selective
antagonist, were able to inhibit mechanically
induced cough in the guinea pig and cat by
an action in the central nervous system (86).
Conclusions
Various anatomic and physiologic properties
of airway afferent neurons change in response
to irritation and inﬂammation in the airways.
Perhaps one of the more dramatic changes
that occurs is the induction of NK synthesis
in airways afferent fibers that under normal
conditions do not normally contain neu-
rokinins. As neurokinin release in the brain
stem may enhance airway reflexes, stimuli
leading to the qualitative change in the type
of airway afferent producing and releasing
tachykinins like that seen following allergen
challenge may contribute to the symptoms of
airway inﬂammation. Thus it may be that in
inflamed airways, it is not only that there is
more neurokinin in the nerves innervating
the airways, but also that the nerves that are
more easily activated (non-nociceptive ﬁbers)
now contain and release neurokinins.
Inflammation is known to induce a similar
qualitative switch in “touch fibers” of the
somato-sensory system so they, like nocicep-
tive C ﬁbers, express substance P. Substance P
released from the central terminals of these
touch ﬁbers appears to contribute to inﬂam-
matory hyperalgesia by enhancing transmis-
sion in the spinal cord and exaggerating the
central response to normally innocuous stim-
uli (87). It is reasonable to speculate that the
release of tachykinins from non-nociceptive
afferent neurons that innervate the airways
will inﬂuence the excitability of synaptic trans-
mission in the central nervous system, such
that the stimulation of these mechanically
sensitive neurons may lead to exaggerated
reﬂex responses to innocuous stimuli.
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